The top after-market NASDAQ stock market gainers are: Cytori Therapeutics, Dendreon, DryShips, Sourcefire, Spreadtrum Communications, Netease.com, Xyratex, Aruba Networks, Exelixis, and Netlist.

Cytori Therapeutics Inc. (CYTX) surged 8.71 percent to $4.87 in the after-market trading.

Dendreon Corp. (DNDN) soared 8.61 percent to $38.96 in the after-hours session. Medicare Evidence Development & Coverage Advisory Committee backed the company's Provenge prostate cancer therapy, helping the U.S. government decide whether to pay for its $93,000 prostate cancer treatment.

DryShips, Inc. (DRYS) jumped 7.51 percent to $5.58 in the after-market trading. The company's third quarter adjusted profit was $99 million or 38 cents a share. Revenue rose to $225.5 million from $222.3 million. Analysts had expected profit of 25 cents a share on revenue of $216.92 million.

Sourcefire, Inc. (FIRE) improved 6.72 percent to $27.15 in the after-hours session.

Spreadtrum Communications Inc. (SPRD) rose 4.17 percent to $16 in the after-market trading. The company's third quarter profit was $19.5 million or 37 cents per ADS, up from $0.6 million or 1 cent per ADS last year. Revenue rose 34.7 percent to $96.2 million. Analysts had expected profit of 33 cents a share on revenue of $92.58 million. Spreadtrum expects fourth quarter revenue of $118 million to $125 million, while analysts forecast $102.64 million.

Netease.com Inc. (NTES) grew 3.49 percent to $42.35 in the after-hours session. The company's third quarter profit was $87.5 million or 67 cents per ADS, up from $57.7 million or 44 cents per ADS last year. Revenue rose to $215.1 million from $128.8 million. Analysts had expected profit of 63 cents per ADS on revenue of $202.71 million.

Xyratex Ltd. (XRTX) gained 2.96 percent to $14.95 in the after-market trading.

Aruba Networks, Inc. (ARUN) increased 2.95 percent to $21.95 in the after-hours session. The company's first quarter adjusted profit was $13.9 million or 12 cents a share, up from $4.1 million or 4 cents a share last year. Revenue rose 44 percent to $83.1 million. Analysts had expected profit of 11 cents a share on revenue of $80.98 million.

Exelixis, Inc. (EXEL) moved up 1.91 percent to $4.81 in the after-market trading. The company posted promising interim data from patients with ovarian cancer treated With XL184 in an ongoing phase 2 adaptive randomized discontinuation trial. 32 percent confirmed response rate per response evaluation criteria in solid tumors in patients with platinum-resistant or platinum-sensitive disease.

Exelixis also reported promising interim data from patients with castration-resistant prostate cancer treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial. 19 of 20 patients (95 percent) achieve complete or partial resolution of lesions on bone scan by independent review.

Netlist Inc. (NLST) rose 1.87 percent to $2.18 in the after-hours session.

NASDAQ Stock Market Cancer Cancer